Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Non Operating Income (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Non Operating Income readings, the most recent being $28.5 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 38.35% to $28.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $86.3 million, a 202.13% increase, with the full-year FY2025 number at $86.3 million, up 202.13% from a year prior.
  • Non Operating Income hit $28.5 million in Q4 2025 for Neurocrine Biosciences, down from $52.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $52.8 million in Q3 2025 to a low of -$78.0 million in Q2 2022.
  • Median Non Operating Income over the past 5 years was $10.5 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Non Operating Income: crashed 1371.7% in 2022 and later soared 712.31% in 2025.
  • Neurocrine Biosciences' Non Operating Income stood at $22.5 million in 2021, then plummeted by 35.56% to $14.5 million in 2022, then surged by 230.34% to $47.9 million in 2023, then plummeted by 56.99% to $20.6 million in 2024, then surged by 38.35% to $28.5 million in 2025.
  • The last three reported values for Non Operating Income were $28.5 million (Q4 2025), $52.8 million (Q3 2025), and $13.9 million (Q2 2025) per Business Quant data.